News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Cash or Perish, Adherex Technologies Inc. Warns Investors
August 25, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DURHAM – With just a little more than $10 million in cash, Adherex Technologies has warned investors that it could be forced to shut down operations without “substantial additional funds.”
Twitter
LinkedIn
Facebook
Email
Print
Bankruptcy
MORE ON THIS TOPIC
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
Delayed Notice Reveals 141 More Layoffs From Genentech in 2025
February 9, 2026
·
52 min read
·
BioSpace Editorial Staff
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac